162 related articles for article (PubMed ID: 21732930)
21. Thalidomide and dexamethasone: therapy for multiple myeloma.
Kumar S; Rajkumar SV
Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in the management of multiple myeloma.
Kumar L; Verma R; Radhakrishnan VR
Natl Med J India; 2010; 23(4):210-8. PubMed ID: 21192514
[TBL] [Abstract][Full Text] [Related]
23. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
24. Genomics in multiple myeloma: biology and clinical implications.
Chng WJ; Fonseca R
Pharmacogenomics; 2005 Sep; 6(6):563-73. PubMed ID: 16142997
[TBL] [Abstract][Full Text] [Related]
25. Management of older adults with multiple myeloma.
Palumbo A; Mina R
Blood Rev; 2013 May; 27(3):133-42. PubMed ID: 23623929
[TBL] [Abstract][Full Text] [Related]
26. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
27. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Gertz MA; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK
Expert Rev Anticancer Ther; 2006 Mar; 6(3):343-60. PubMed ID: 16503852
[TBL] [Abstract][Full Text] [Related]
28. Optimising patient outcomes in myeloma.
Harousseau JL
Cancer Treat Rev; 2010 May; 36 Suppl 2():S33-5. PubMed ID: 20472187
[TBL] [Abstract][Full Text] [Related]
29. Recent trends in the management of newly diagnosed multiple myeloma.
Reece DE
Curr Opin Hematol; 2009 Jul; 16(4):306-12. PubMed ID: 19491669
[TBL] [Abstract][Full Text] [Related]
30. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
31. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
[TBL] [Abstract][Full Text] [Related]
32. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
[TBL] [Abstract][Full Text] [Related]
33. Novel therapies in myeloma.
Hayden PJ; Mitsiades CS; Anderson KC; Richardson PG
Curr Opin Hematol; 2007 Nov; 14(6):609-15. PubMed ID: 17898564
[TBL] [Abstract][Full Text] [Related]
34. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
[TBL] [Abstract][Full Text] [Related]
35. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
36. The importance of complete response in outcomes in myeloma.
Nooka A; Kaufman J; Lonial S
Cancer J; 2009; 15(6):465-72. PubMed ID: 20010165
[TBL] [Abstract][Full Text] [Related]
37. Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors.
Driscoll JJ; Brailey M
Cancer Metastasis Rev; 2017 Dec; 36(4):585-598. PubMed ID: 29052093
[TBL] [Abstract][Full Text] [Related]
38. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
[TBL] [Abstract][Full Text] [Related]
39. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.
Benevolo G; Larocca A; Gentile M; Pregno P; Gay F; Botto B; Frairia C; Evangelista A; Morabito F; Boccadoro M; Vitolo U; Palumbo A
Cancer; 2011 May; 117(9):1884-90. PubMed ID: 21509765
[TBL] [Abstract][Full Text] [Related]
40. Myeloma: classification and risk assessment.
Fonseca R; Monge J
Semin Oncol; 2013 Oct; 40(5):554-66. PubMed ID: 24135400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
